Lv1
100 积分 2024-02-20 加入
Discovery of the First Potent PI3K/mTOR Dual-Targeting PROTAC Degrader for Efficient Modulation of the PI3K/AKT/mTOR Pathway
3个月前
已完结
Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy
4个月前
已完结
Species cross-reactivity of anti-CD20 antibodies: From human to companion animals
5个月前
已关闭
Enrichment of innate immune cells from PBMC followed by triple cytokine activation for adoptive immunotherapy
8个月前
已完结
皖公网安备34019202002308
